Butyrate inhibits pancreatic cancer invasion.
Pancreatic cancer is the most deadly gastrointestinal malignancy because of its propensity for local invasion and early metastasis. Integrin chains, in particular beta4, can promote invasion in other cancers. The effect of sodium butyrate (NaBT), which induces differentiation in transformed cells, on integrin expression is unknown. The purpose of this study was to determine patterns of integrin expression in pancreatic cancer cells and investigate the effect of NaBT on integrin expression and invasion. Integrin expression was assessed in the less invasive MIA-PaCa-2 and PANC-1 and more invasive L3.6, AsPC-1, and SUIT-2 human pancreatic cancer cell lines by ribonuclease (RNase) protection assay. Western blotting and immunofluorescent staining for beta4 expression was determined after NaBT treatment. Matrigel invasion chambers were used to assess pancreatic cancer cell invasion. beta4 and beta7 integrin expression was highest in L3.6, AsPC-1, and SUIT-2 cells. NaBT reduced the expression of beta4 integrin in AsPC-1 cells including less cell surface beta4. Invasion of AsPC-1 cells was also reduced by NaBT. Expression of beta4 is higher in more aggressive pancreatic cancer cells; NaBT inhibits beta4 expression and invasion. NaBT may represent a novel strategy to inhibit pancreatic cancer invasion and improve the prognosis of this deadly disease.
Department of Surgery, The University of Texas Medical Branch, Galveston, Texas 77555, USA.
Buckminster
B
Farrow
Piotr
P
Rychahou
Kathleen L
KL
O'Connor
B Mark
BM
Evers
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002087:Butyrates / Q000494:pharmacology*; D045744:Cell Line, Tumor; D015870:Gene Expression; D006801:Humans; D039663:Integrin beta4 / Q000235:genetics / Q000502:physiology; D016023:Integrins / Q000235:genetics / Q000502:physiology*; D009361:Neoplasm Invasiveness; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology
D000970:Antineoplastic Agents; D002087:Butyrates; D039663:Integrin beta4; D016023:Integrins